FARRELL PETER C 4

What Happened

• Peter C. Farrell, a director of Arcturus Therapeutics Holdings, received a grant (derivative award) covering 15,000 underlying shares on June 5, 2026. The reported acquisition price is $0.00, so no cash was paid per the filing. This is an annual board compensation grant rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Filing date (Form 4): 2026-06-15 (filed 10 days after the transaction).
• Transaction type/code: A = Award/Grant of derivative securities (15,000 underlying shares); reported price $0.00.
• Vesting: Footnote F1 — shares underlying the option vest monthly over a one‑year period; this is the 2026 annual board grant.
• Shares owned after transaction: not disclosed in the provided filing.
• Timeliness: The Form 4 was filed 10 days after the grant; this is later than the standard 2-business-day reporting window for Form 4s.

Context

• This filing reports a compensation grant to a board member (routine annual award) and not an immediate purchase or sale of shares. Because the award vests over a year and was granted at $0.00 (per the filing), there is no immediate change in market holdings or proceeds to the insider. Such grants are standard director compensation and do not by themselves indicate a buy or sell signal.